(Press-News.org) BOSTON—Men who illicitly used steroids to boost muscle size and physical performance and have stopped in the past year have impaired sexual function compared with men currently using steroids, according to a study being presented Sunday at ENDO 2024, the Endocrine Society’s annual meeting in Boston, Mass.
Having a psychiatric diagnosis and stopping steroids was associated with greater impairment in sexual function, the researchers found.
“It is important to recognize the symptoms that men experience within the first year of stopping steroids,” said lead researcher Bonnie Grant, M.B.B.S., of Imperial College London in London, U.K. “We observed that some factors such as psychiatric diagnosis and lower testosterone levels may contribute to worse symptoms of depression and sexual dysfunction.”
Millions of men worldwide illicitly use anabolic-androgenic steroids. These substances act like the male hormone testosterone to increase muscle growth, enhance body physique, and improve athletic performance. Using steroids is dangerous as they can lead to heart attacks, strokes, high blood pressure, mental health problems and even death, Grant said.
Steroids stop the body from producing natural testosterone in men. When steroids are stopped, there is often a delay in the body making natural testosterone. During this time, men report feeling a low sex drive, low mood, anxiety, suicidal thoughts, with an overall decline in wellbeing. “There are currently no treatments which doctors can give these men to reduce these symptoms, and often men restart using steroids,” said Channa Jayasena M.D., Ph.D., the senior study author. He noted that no previous studies have focused on measuring symptoms within the first year of stopping steroids or investigated independently associated factors for these symptoms.
Grant and colleagues collected data from 165 men across England. Of these, 43 men had never used steroids, 76 were currently using steroids and 46 had stopped using steroids within the last 12 months. The men were asked about symptoms of sexual function, depression, anxiety, and quality of life. They also had a blood test done for testosterone and other reproductive hormone levels.
The study found that men stopping steroids less than one year ago had a 12% lower sexual function score compared with men currently using steroids. Erectile function, sexual desire and overall satisfaction scores were lower in men stopping steroids compared to men currently using steroids. Having a psychiatric diagnosis and stopping steroids was associated with greater impairment in sexual function.
Depression scores were 75% higher in men who stopped using steroids within the last year compared with men who had never used steroids. Having a psychiatric diagnosis and lower testosterone levels was associated with higher depression scores. Men who had stopped using steroids also were less energetic and more fatigued compared with men who had never used steroids.
“These data reveal potentially treatable factors to improve symptoms men experience when they stop using steroids,” Grant said.
Grant is scheduled to speak at the Society's reproductive health news conference at 11 a.m. Eastern June 2. Register to view the livestream at endomediastream.com.
# # #
Endocrinologists are at the core of solving the most pressing health problems of our time, from diabetes and obesity to infertility, bone health, and hormone-related cancers. The Endocrine Society is the world’s oldest and largest organization of scientists devoted to hormone research and physicians who care for people with hormone-related conditions.
The Society has more than 18,000 members, including scientists, physicians, educators, nurses and students in 122 countries. To learn more about the Society and the field of endocrinology, visit our site at www.endocrine.org. Follow us on Twitter at @TheEndoSociety and @EndoMedia.
END
BOSTON—Women experiencing moderate-to-severe vasomotor symptoms face a three times greater risk for metabolic-dysfunction-associated steatotic liver disease (MASLD) compared to those with mild symptom severity, according to research being presented Monday at ENDO 2024, the Endocrine Society’s annual meeting in Boston, Mass.
Vasomotor symptoms include hot flashes or night sweats—symptoms that have become synonymous with menopause.
“This research is significant as it contributes ...
The world of robotics is witnessing a transformative shift with the rise of soft robotics, which offers unparalleled flexibility and adaptability in various applications, from medical interventions to intricate rescue operations. A groundbreaking review article by Zhou et al. published in Cyborg Bionic Systems in 2024, sheds light on this evolution, highlighting the crucial integration of actuation and sensing technologies that pave the way for truly intelligent soft robots.
Soft robots, unlike their rigid counterparts, are made from materials that mimic the mechanical properties of living tissues, allowing them to move and adapt with a life-like grace. This capability makes ...
BOSTON—Almost one out of five breast cancer survivors may experience weight gain of more than 10%, suggests a study presented Monday at ENDO 2024, the Endocrine Society’s annual meeting in Boston, Mass. A number of factors are associated with excessive weight gain, the researchers found.
Factors associated with more than 10% weight gain included a lower weight, younger age, and more advanced cancer stage at cancer diagnosis; hormone-positive breast cancer; mutations of the BRCA2 gene; undergoing more aggressive breast surgery; and the use of chemotherapy and endocrine therapy, the study found.
“Weight ...
An immunotherapy drug given before surgery instead of chemotherapy meant that over ten times more patients with a certain genetic profile were cancer free after surgery, according to clinical trial results presented by researchers at UCL and UCLH.
The findings, presented at the American Society of Clinical Oncology (ASCO) Annual Meeting 2024, are interim results from the NEOPRISM-CRC phase II clinical trial assessing whether the immunotherapy drug pembrolizumab can improve outcomes for patients with stage two or stage three MMR deficient/MSI-High bowel cancer. The ...
About The Study: A stepped-care model, with palliative care visits occurring only at key points in patients’ cancer trajectories and using a decrement in quality of life to trigger more intensive palliative care exposure, resulted in fewer palliative care visits without diminishing the benefits for patients’ quality of life. While stepped palliative care was associated with fewer days in hospice, it is a more scalable way to deliver early palliative care to enhance patient-reported outcomes.
Quote from corresponding author Jennifer S. Temel, M.D.:
“This study demonstrates that early palliative ...
BOSTON – A new study led by investigators from Mass General Cancer Center, a founding member of the Mass General Brigham healthcare system, reveals the effectiveness of more scalable ways of delivering palliative care to patients with advanced lung cancer. The findings were highlighted at the American Society of Clinical Oncology’s annual meeting and are published in JAMA.
The study, led by Jennifer S. Temel, MD of the Mass General Cancer Center, assessed the effectiveness of stepped palliative care, in which all patients receive palliative care for their condition, but with a minimum of required contact with a specialty-trained clinician. ...
Berlin, Germany: Differences in socioeconomic status (SES) are known to be linked to differences in the risk of developing disease. While people with lower SES are more likely to develop complex diseases such as diabetes and cardiovascular disease, those with a higher SES are at increased risk of developing certain types of cancer. Using biobank and national register data, researchers from Finland have now found that people with lower SES (educational achievement and occupation) have a greater genetic susceptibility to develop many other complex diseases such as rheumatoid arthritis, lung cancer, depression, and alcohol ...
CHICAGO – While CAR T cell therapy has revolutionized treatment for many blood cancers, including non-Hodgkin lymphoma (NHL), many patients who receive CAR T cell therapy do not experience a long-term remission. For those whose cancers return or become resistant after CAR T cell therapy, the prognosis is poor, with few options left.
A new “armored” form of CAR T cell therapy, developed by Carl June, MD, the Richard W. Vague Professor in Immunotherapy in the Perelman School of Medicine at the University ...
BOSTON—People who have had type 1 diabetes for more than 50 years without kidney complications may still be at substantial risk for heart disease, despite excellent control of blood pressure, cholesterol and blood sugar levels, according to a study presented Saturday at ENDO 2024, the Endocrine Society’s annual meeting in Boston, Mass.
Heart disease is a major cause of death in people with type 1 diabetes, especially in those who develop kidney complications from diabetes.
“As people with type 1 diabetes live longer due to improved medical care, a substantial proportion of these patients survive without kidney complications, but are still at high risk for heart ...
BOSTON—Medications for type 2 diabetes and obesity known as GLP-1 receptor agonists may lower the risk of acute pancreatitis recurrence in people with obesity and those with type 2 diabetes, according to a study presented Saturday at ENDO 2024, the Endocrine Society’s annual meeting in Boston, Mass.
Doctors have been cautious about prescribing these medications in patients with a history of pancreatitis due to the potential risk of worsening the condition – a warning that is included in prescribing information, said lead researcher Mahmoud Nassar, M.D., Ph.D., Department of Medicine ...
